Eris Lifesciences Limited
シンボルマーク: ERIS.NS
NSE
873.35
INR今日の市場価格
30.7423
PER(株価収益率
1.6041
PEGレシオ
118.82B
MRK キャップ
- 0.00%
DIV利回り
Eris Lifesciences Limited (ERIS-NS) 財務諸表
貸借対照表
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 5613.44 | 892.4 | 1772.4 | 522.7 | |||||||||||
balance-sheet.row.short-term-investments | 6124.75 | 332.2 | 1264.5 | 154 | |||||||||||
balance-sheet.row.net-receivables | 6515.97 | 2966.9 | 2260.9 | 2280.6 | |||||||||||
balance-sheet.row.inventory | 2705.24 | 1314.3 | 1179.1 | 944.7 | |||||||||||
balance-sheet.row.other-current-assets | 5222.75 | 2473.5 | 1060.8 | 922.5 | |||||||||||
balance-sheet.row.total-current-assets | 20057.4 | 7647.2 | 6273.3 | 4670.5 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 7998.42 | 3773.8 | 1918.6 | 778.8 | |||||||||||
balance-sheet.row.goodwill | 6636.98 | 3318.5 | 934.7 | 934.7 | |||||||||||
balance-sheet.row.intangible-assets | 37042.03 | 18806 | 6596 | 6840.8 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 43679.01 | 22124.5 | 7530.7 | 7775.5 | |||||||||||
balance-sheet.row.long-term-investments | 16.43 | 68.8 | 4208.4 | 2859.2 | |||||||||||
balance-sheet.row.tax-assets | 5690.48 | 2739.4 | 2431.3 | 2006.3 | |||||||||||
balance-sheet.row.other-non-current-assets | -2016.58 | 319.6 | 359 | 257.6 | |||||||||||
balance-sheet.row.total-non-current-assets | 55367.76 | 29026.1 | 16448.1 | 13677.3 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 75425.16 | 36673.3 | 22721.4 | 18347.8 | |||||||||||
balance-sheet.row.account-payables | 2752.94 | 1247.7 | 1177.7 | 1026.2 | |||||||||||
balance-sheet.row.short-term-debt | 3903.21 | 1932.9 | 40.1 | 23.3 | |||||||||||
balance-sheet.row.tax-payables | 176.96 | 39 | 70 | 77.5 | |||||||||||
balance-sheet.row.long-term-debt-total | 13158.94 | 6834.2 | 803.9 | 44.5 | |||||||||||
Deferred Revenue Non Current | 623.49 | 87.4 | 56.9 | 61.1 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 5109.42 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 438.6 | 217.2 | 152.4 | 132.5 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 19538.95 | 10034.2 | 1642.9 | 914.3 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 903 | 466.9 | 394 | 67.7 | |||||||||||
balance-sheet.row.total-liab | 28942.66 | 14466.5 | 3639.4 | 2583.6 | |||||||||||
balance-sheet.row.preferred-stock | 21930.12 | 21930.1 | 19062.4 | 15722.7 | |||||||||||
balance-sheet.row.common-stock | 272.01 | 136 | 135.9 | 135.8 | |||||||||||
balance-sheet.row.retained-earnings | 21559.3 | 21559.3 | 18736.5 | 15503.1 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 70084.98 | 29.8 | 20.7 | 41.5 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | -21288.35 | -21695.3 | -18872.5 | -15638.9 | |||||||||||
balance-sheet.row.total-stockholders-equity | 92558.06 | 21959.9 | 19083.1 | 15764.2 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 121907.66 | 36673.3 | 22721.4 | 18347.8 | |||||||||||
balance-sheet.row.minority-interest | 406.94 | 246.9 | -1.1 | 0 | |||||||||||
balance-sheet.row.total-equity | 92965 | 22206.8 | 19082 | 15764.2 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 121907.66 | - | - | - | |||||||||||
Total Investments | 5883.66 | 143.5 | 4208.4 | 2436.4 | |||||||||||
balance-sheet.row.total-debt | 17062.15 | 8767.1 | 844.1 | 67.8 | |||||||||||
balance-sheet.row.net-debt | 17573.46 | 8206.9 | 336.1 | -300.9 |
キャッシュフロー計算書
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 3864.39 | 4046.4 | 4422 | 3945 | |||||||||||
cash-flows.row.depreciation-and-amortization | 1638.34 | 1170.9 | 647 | 429.9 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | -809.7 | -976.6 | -670.9 | |||||||||||
cash-flows.row.stock-based-compensation | 31.21 | 31.2 | 13.6 | 11.2 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | -1755.4 | -299 | 53.3 | |||||||||||
cash-flows.row.account-receivables | 0 | -1171.4 | -204.8 | 159 | |||||||||||
cash-flows.row.inventory | 0 | 47.4 | -234.4 | -249.9 | |||||||||||
cash-flows.row.account-payables | 0 | -105 | 151.6 | 25.7 | |||||||||||
cash-flows.row.other-working-capital | 0 | -526.5 | -11.3 | 118.6 | |||||||||||
cash-flows.row.other-non-cash-items | -3895.6 | 233.9 | -24.4 | -14.7 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 2605.29 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -8414.2 | -1210.3 | -257.6 | |||||||||||
cash-flows.row.acquisitions-net | 0 | -6554.9 | -103 | -2.8 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | -300 | -2677.7 | -3733.9 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 5204.4 | 795.9 | 774.2 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 243.7 | -1 | -13.4 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -9821 | -3196.1 | -3233.6 | |||||||||||
cash-flows.row.debt-repayment | 0 | -3500 | -450 | -0.1 | |||||||||||
cash-flows.row.common-stock-issued | 0 | 22.8 | 67.5 | 0 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 3477.2 | -450 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | -999.1 | -816.2 | -746.8 | |||||||||||
cash-flows.row.other-financing-activites | 0 | 7879.4 | 1201.8 | -77.1 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 6880.3 | -447 | -824 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 74.9 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 2605.29 | 51.5 | 139.6 | -303.9 | |||||||||||
cash-flows.row.cash-at-end-of-period | 6306.92 | 560.2 | 508.7 | 369.1 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 3701.63 | 508.7 | 369.1 | 673.1 | |||||||||||
cash-flows.row.operating-cash-flow | 2605.29 | 2917.4 | 3782.6 | 3753.6 | |||||||||||
cash-flows.row.capital-expenditure | 0 | -8414.2 | -1210.3 | -257.6 | |||||||||||
cash-flows.row.free-cash-flow | 2605.29 | -5496.8 | 2572.3 | 3496 |
損益計算書の行
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 18406.22 | 16618.2 | 13261.7 | 11926.4 | |||||||||||
income-statement-row.row.cost-of-revenue | 3346.18 | 3523.5 | 2608.1 | 2418.7 | |||||||||||
income-statement-row.row.gross-profit | 15060.04 | 13094.7 | 10653.6 | 9507.8 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 61 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 1189.54 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 63.85 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 96.71 | 111.5 | 10.4 | 4.5 | |||||||||||
income-statement-row.row.operating-expenses | 10245.46 | 8898.1 | 6403 | 5620 | |||||||||||
income-statement-row.row.cost-and-expenses | 13591.64 | 12421.6 | 9011.1 | 8038.7 | |||||||||||
income-statement-row.row.interest-income | 402.19 | 23 | 61 | 22.9 | |||||||||||
income-statement-row.row.interest-expense | 606.36 | 261.7 | 41.5 | 18 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 63.85 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -596.47 | -170.2 | 176.9 | 68.9 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 96.71 | 111.5 | 10.4 | 4.5 | |||||||||||
income-statement-row.row.total-operating-expenses | -596.47 | -170.2 | 176.9 | 68.9 | |||||||||||
income-statement-row.row.interest-expense | 606.36 | 261.7 | 41.5 | 18 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 1638.34 | 1170.9 | 647 | 429.9 | |||||||||||
income-statement-row.row.ebitda-caps | 6549.63 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 4901.4 | 4216.6 | 4245 | 3876.1 | |||||||||||
income-statement-row.row.income-before-tax | 4304.93 | 4046.4 | 4422 | 3945 | |||||||||||
income-statement-row.row.income-tax-expense | 515.94 | 304.8 | 364.1 | 393.6 | |||||||||||
income-statement-row.row.net-income | 3864.39 | 3821.6 | 4061.1 | 3551.3 |
よくある質問
Eris Lifesciences LimitedERIS.NS 総資産とは何ですか?
Eris Lifesciences Limited (ERIS.NS) 総資産は 36673280000.000.
企業の年間売上高とは?
年間収益は 9840010000.000である.
企業の利益率は?
利益率は 0.818 である.
企業のフリーキャッシュフローとは?
フリーキャッシュフローは 19.153.
企業の純利益率は?
純利益率は 0.210 である.
企業の総収入は?
総収入は 0.266 である.
Eris Lifesciences Limited (ERIS.NS) 純利益(純利益)とは何ですか?
純利益(純利益)は 3821580000.000.
負債総額は?
負債合計は 8767110000.000 である.
営業費用はいくらですか?
営業費用は 8898080000.000 である.
会社の現金はいくらですか?
企業の現金は -1906240000.000 である.